Key result
In spontaneously hypertensive rats, intravenous infusion of EET-A or AAA significantly increased renal blood flow by approximately 30-40% and decreased mean arterial blood pressure, with no additive effect observed when combined.
Why the study?
EETs deficiency and increased renal formation of 20-HETE contribute to hypertension in spontaneously hypertensive rats, prompting exploration of the effects of EET-A and AAA on blood pressure and kidney function.
Does EET-A and/or AAA improve renal hemodynamics and lower blood pressure in spontaneously hypertensive rats?
Does EET-A and/or AAA improve renal hemodynamics and lower blood pressure in spontaneously hypertensive rats?
Both EET-A and AAA induce early renal vasodilation and lower blood pressure in spontaneously hypertensive rats, though their combination does not yield additive acute effects.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for EET-A/AAA renal effects in hypertension models; leaves open human translation.
Cytochrome P450 (CYP-450) metabolites of arachidonic acid: epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) have established role in regulation of blood pressure (BP) and kidney function. EETs deficiency and increased renal formation of 20-HETE contribute to hypertension in spontaneously hypertensive rats (SHR). We explored the effects of 14,15-EET analog (EET-A) and of 20-HETE receptor blocker (AAA) on BP and kidney function in this model. In anesthetized SHR the responses were determined of mean arterial blood pressure (MABP), total renal (RBF), and cortical (CBF) and inner-medullary blood flows, glomerular filtration rate and renal excretion, to EET-A, 5 mg/kg, infused i.v. for 1 h to rats untreated or after blockade of endogenous EETs degradation with an inhibitor (c-AUCB) of soluble epoxide hydrolase. Also examined were the responses to AAA (10 mg/kg/h), given alone or together with EET-A. EET-A significantly increased RBF and CBF (+30% and 26%, respectively), seen already within first 30 min of infusion. The greatest increases in RBF and CBF (by about 40%) were seen after AAA, similar when given alone or combined with EET-A. MABP decreased after EET-A or AAA but not significantly after the combination thereof. In all groups, RBF, and CBF increases preceded the decrease in MABP. We found that in SHR both EET-A and AAA induced renal vasodilation but, unexpectedly, no additive effect was seen. We suggest that both agents have a definite therapeutic potential and deserve further experimental and clinical testing aimed at introduction of novel antihypertensive therapy.
No takes yet. Share an insight, caveat, or question.
Walkowska et al. (2021) studied Hypertension (n=42). EET-A and AAA vs. Saline solvent was evaluated on Total renal blood flow (RBF) (p=<0.05). In spontaneously hypertensive rats, intravenous infusion of EET-A or AAA significantly increased renal blood flow by approximately 30-40% and decreased mean arterial blood pressure, with no additive effect observed when combined.
Synapse has enriched 10 related papers. Consider them for comparative context: